What is iron saccharate used for?

Iron saccharate is used intravenously to treat iron-deficiency anemia, most commonly in patients with chronic kidney disease on hemodialysis who cannot absorb adequate iron orally or who do not respond to oral supplementation. It is also used in patients with inflammatory bowel disease, post-partum iron deficiency, and those receiving erythropoiesis-stimulating agents who require iron support to maintain hemoglobin targets above 10–11 g/dL.

How is iron saccharate administered and what is the typical dose?

Iron saccharate is administered as a slow intravenous infusion or injection, typically in doses of 100–200 mg elemental iron per session, given over 2–5 minutes for injection or 15–30 minutes for infusion. Hemodialysis patients commonly receive a cumulative repletion dose of 1,000 mg over 10 sequential dialysis sessions, after which maintenance doses are adjusted based on serum ferritin and transferrin saturation (TSAT) levels.

How does iron saccharate differ from ferric carboxymaltose?

Iron saccharate (ferric sucrose) requires multiple smaller doses, typically 100–200 mg per administration, because higher single doses carry a greater risk of free iron release and oxidative stress, whereas ferric carboxymaltose can be administered as a single dose of up to 1,000 mg in 15 minutes due to its more stable carbohydrate shell. Both compounds deliver ferric iron to transferrin and the reticuloendothelial system, but ferric carboxymaltose is more convenient for outpatient settings, while iron saccharate has a longer clinical track record in dialysis populations.

Is iron saccharate safe during pregnancy?

Iron saccharate is generally avoided during the first trimester due to theoretical risks of fetal exposure during organogenesis, though animal reproductive studies have not demonstrated teratogenicity. In the second and third trimesters, it is considered a treatment option for severe iron-deficiency anemia unresponsive to oral iron, and limited clinical data suggest it does not significantly cross the placental barrier at standard therapeutic doses; the decision to use it should be made on a risk-benefit basis under medical supervision.

Can iron saccharate cause iron overload?

Yes, repeated administration of iron saccharate without monitoring can lead to iron overload, characterized by elevated serum ferritin above 800 ng/mL and transferrin saturation exceeding 50%, which can cause oxidative tissue damage to the liver, heart, and pancreas. Clinical guidelines recommend monitoring ferritin and TSAT levels before each course of therapy, and treatment should be withheld if ferritin exceeds 500–800 ng/mL depending on institutional protocols, to prevent hemosiderosis in high-risk patients such as those on long-term hemodialysis.

What are the common side effects of iron saccharate?

Iron saccharate is generally well-tolerated when administered intravenously, with a lower incidence of gastrointestinal side effects compared to oral iron supplements. The most commonly reported adverse effects include injection site reactions, headache, and transient hypotension. Serious adverse reactions are rare but may include anaphylaxis or iron overload if dosing guidelines are not followed appropriately.

Who should avoid iron saccharate supplementation?

Iron saccharate should be avoided in patients with iron overload conditions such as hemochromatosis or hemosiderosis, as well as those with acute infections where iron supplementation may be contraindicated. Patients with known hypersensitivity to iron compounds or saccharate excipients should not receive this medication. Those with certain types of anemia unrelated to iron deficiency should consult a healthcare provider before use, as iron supplementation may be inappropriate.

How does iron saccharate compare to other intravenous iron formulations in terms of patient outcomes?

Iron saccharate has been used clinically for decades as an intravenous iron therapy, particularly in chronic kidney disease populations, though direct comparative trial data with newer formulations is limited. While it remains an effective option for iron repletion in patients intolerant of oral iron, some newer IV iron formulations may offer different dosing schedules or safety profiles. The choice between iron saccharate and alternative IV formulations should be based on individual patient factors, availability, and clinical judgment.

Iron Saccharate

Iron saccharate is an intravenous iron complex composed of ferric iron stabilized within a sucrose shell, used primarily to replenish iron stores in patients with iron-deficiency anemia, particularly those with chronic kidney disease. It restores hemoglobin synthesis by delivering bioavailable ferric iron directly to the reticuloendothelial system, bypassing gastrointestinal absorption limitations.

Category: Mineral Evidence: 2/10 Tier: Emerging

Iron Saccharate — Hermetica Encyclopedia

Origin & History

Iron saccharate is a synthetic iron(III)-carbohydrate complex with no natural origin, chemically synthesized by complexing ferric iron with saccharate derived from glucaric acid or sucrose components. It forms a polynuclear iron(III)-hydroxide sucrose complex with molecular formulas like C₁₈H₂₄Fe₂O₂₄, appearing as a brown to dark brown solid with a melting point of 168-171°C.

Historical & Cultural Context

Iron saccharate is a modern synthetic pharmaceutical with no documented historical or traditional use in any medicine systems. It belongs to the chemical class of trivalent iron preparations (ATC code B03AB02) developed for clinical use.

Health Benefits

• Treatment of iron-deficiency anemia in chronic kidney disease patients when oral iron therapy is ineffective (established clinical use, no specific trial data provided) • Intravenous iron supplementation for patients unable to tolerate oral iron (clinical indication mentioned, no evidence quality specified) • No additional benefits documented in the provided research • No clinical trial outcomes or effect sizes available in the research dossier • Limited evidence base as search results lack specific human trial data

How It Works

Iron saccharate dissociates in the bloodstream, releasing ferric iron (Fe³⁺) that is taken up by the reticuloendothelial system via receptor-mediated endocytosis, primarily through transferrin receptor 1 (TfR1) on erythroid precursors. The released iron binds to transferrin, forming diferric transferrin, which delivers iron to bone marrow erythroblasts to support heme biosynthesis through ferrochelatase-mediated incorporation into protoporphyrin IX. Additionally, iron replenishes ferritin stores, upregulating iron-responsive element (IRE) binding protein activity and restoring systemic iron homeostasis.

Scientific Research

The research dossier explicitly states that search results lack specific details on key human clinical trials, RCTs, or meta-analyses for iron saccharate, with no PubMed PMIDs provided. Available data only generally describe its established use for iron-deficiency anemia in CKD patients when oral therapy fails, but no study designs, sample sizes, or outcomes are documented.

Clinical Summary

Iron saccharate (ferric sucrose, marketed as Venofer) has been evaluated in multiple randomized controlled trials and observational studies in hemodialysis and peritoneal dialysis patients, with sample sizes typically ranging from 50 to 500 participants. In hemodialysis patients receiving erythropoiesis-stimulating agents (ESAs), intravenous iron saccharate has been shown to increase hemoglobin by approximately 1–2 g/dL and reduce ESA requirements by 20–40% compared to oral iron supplementation. Evidence quality for its use in chronic kidney disease is considered high based on consistent RCT data, though head-to-head comparisons with other IV iron formulations such as ferric carboxymaltose show broadly similar efficacy with minor differences in dosing convenience. Evidence in non-CKD populations such as inflammatory bowel disease or post-partum anemia is less robust, relying primarily on smaller open-label trials.

Nutritional Profile

Iron Saccharate (also known as Saccharated Iron Oxide or Iron Sucrose in related forms) is a therapeutic intravenous iron preparation, not a dietary nutrient source. Key compositional data: Elemental iron content approximately 20 mg/mL (2%) in standard IV formulations, complexed with sucrose as a stabilizing carbohydrate ligand. The iron is present in the ferric (Fe³⁺) state bound within a polynuclear iron(III)-hydroxide core stabilized by sucrose molecules. Molecular weight of the complex approximately 34,000–60,000 Da. Each standard vial (5 mL) typically delivers 100 mg elemental iron. Sucrose (carbohydrate) component contributes approximately 300 mg per 100 mg iron dose, relevant for diabetic patients. No protein, fiber, fat, or additional micronutrient content. No vitamins present. Bioavailability notes: Administered exclusively via intravenous route, bypassing gastrointestinal absorption entirely, achieving near 100% bioavailability of elemental iron directly into systemic circulation. Iron is taken up by the reticuloendothelial system (macrophages in liver, spleen, bone marrow), released from the complex, bound to transferrin, and incorporated into hemoglobin synthesis. Not orally bioavailable due to complex degradation and poor GI absorption profile. No dietary reference intake (DRI) applicable; dosing is purely clinical and weight/hemoglobin-based.

Preparation & Dosage

No clinically studied dosage ranges, forms, or standardization details are specified in the available research. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

No synergistic ingredients documented in research

Safety & Interactions

The most common adverse effects of iron saccharate include hypotension, nausea, headache, and injection site reactions, occurring in approximately 5–10% of patients; serious hypersensitivity reactions are rare but require monitoring during infusion. Iron saccharate may reduce the absorption of concomitant oral iron supplements and can interact with ACE inhibitors, potentially increasing the risk of systemic reactions including flushing and hypotension. Contraindications include known iron overload conditions (e.g., hemochromatosis), anemia not caused by iron deficiency, and prior hypersensitivity to iron saccharate or its excipients. Pregnancy category B data in animals show no fetal harm, but human safety data are limited and use during the first trimester is generally avoided; it is considered compatible with breastfeeding based on low transfer into breast milk.